17β-N-(tert-butylcarbamoyl)-4-aza-5α-androst-1-ene-3-one

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17β-N-(tert-butylcarbamoyl)-4-aza-5α-androst-1-ene-3-one
• 英文别名: (1S,9aR,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
• 化学式: C₂₃H₃₆N₂O₂
• 分子量: 372.551
• InChiKey: DBEPLOCGEIEOCV-BYQKQGHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1S,9aR,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-8-phenylsulfanyl-1,2,3,3a,3b,4,5,5a,6,8,9,9b,10,11-tetradecahydroindeno[5,4-f]quinoline-1-carboxamide 在 sodium periodate 作用下， 以 甲醇 、 水 为溶剂， 反应 16.0h， 生成 17β-N-(tert-butylcarbamoyl)-4-aza-5α-androst-1-ene-3-one
  参考文献：
  名称：

  US2007/117982

  摘要：

  公开号：

文献信息

• METHOD OF TREATING MEN WITH ERECTILE DYSFUNCTION
  申请人：Meehan Alan

  公开号：US20110092470A1

  公开（公告）日：2011-04-21

  A method of treating male sexual dysfunction or erectile dysfunction by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  本文描述了一种通过使用5α还原酶抑制剂和睾酮补充剂来治疗男性性功能障碍或勃起功能障碍的方法。该方法还涉及使用5α还原酶抑制剂和睾酮补充剂与其他用于治疗勃起功能障碍的药物一起使用，包括PDE V抑制剂；AGE（高级糖基化终产物）破坏剂；α1受体阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑色素细胞激素激动剂；催产素激动剂；前列腺素；自由基清除剂；旋转酶抑制剂；aviptadil；硝酸甘油；以及GPCR激动剂，用于治疗男性性功能障碍或勃起功能障碍。
• 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2305352A1

  公开（公告）日：2011-04-06

  A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the 'insulin resistance syndrome', and 'syndrome X'), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural formula I, II, III, or IV is disclosed. The method is also concerned with the use of the 5alpha reductase inhibiting compound together with antidiabetic agents, lipid lowering agents, antihypertensive agents, antiobesity agents, testosterone, testosterone precursors, testosterone prodrugs, testosterone analogs, and other androgen receptor agonists for treating visceral adiposity, metabolic syndrome, type II diabetes and insulin resistance in men.

  本发明公开了一种通过施用结构式 I、II、III 或 IV 的 5-α 还原酶抑制化合物，安全、特异地治疗患有内脏脂肪过多、代谢综合征（也称为 "胰岛素抵抗综合征 "和 "X 综合征"）、II 型糖尿病或胰岛素抵抗的男性患者的胰岛素抵抗和内脏脂肪过多的合并代谢紊乱的方法。该方法还涉及 5α还原酶抑制化合物与抗糖尿病药、降脂药、降压药、抗肥胖药、睾酮、睾酮前体、睾酮原药、睾酮类似物和其他雄激素受体激动剂一起用于治疗男性内脏脂肪、代谢综合征、II 型糖尿病和胰岛素抵抗。
• Method of treating men with testosterone supplement and 5alpha reductase inhibitor
  申请人：MERCK SHARP & DOHME (I.A.) CORP.

  公开号：EP2371367A1

  公开（公告）日：2011-10-05

  A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile dysfunction, including PDE V inhibitors; AGE (advanced glycation end-product) breakers; alpha 1 blockers; alpha 1A antagonists; alpha 2 antagonists; dopamine agonists; dopamine D4 agonists; melanocortin agonists; oxytocin agonists; prostaglandin; radical scavengers; rotamase inhibitors; aviptadil; nitroglycerine; and GPCR agonists for treating male sexual dysfunction or erectile dysfunction.

  描述了一种通过服用 5α 还原酶抑制剂和睾酮补充剂来治疗阿尔茨海默病、帕金森病、性功能障碍或男性勃起功能障碍的方法。该方法还涉及将 5α 还原酶抑制化合物和睾酮补充剂与另一种治疗勃起功能障碍的药物一起使用，包括 PDE V 抑制剂；AGE（高级糖化终产物）分解剂；α 1 阻滞剂；α1A拮抗剂；α2拮抗剂；多巴胺激动剂；多巴胺D4激动剂；黑皮质素激动剂；催产素激动剂；前列腺素；自由基清除剂；腐胺酶抑制剂；阿维他地尔；硝酸甘油；以及治疗男性性功能障碍或勃起功能障碍的GPCR激动剂。
• Method for producing 1,2-unsaturated azasteroids
  申请人：Jasic Muhamed

  公开号：US20070117982A1

  公开（公告）日：2007-05-24

  The invention relates to a method for producing 1,2-unsaturated azasteroids of general formula (I), from a structurally related, saturated azasteroid of general formula (II).
• Method of Treating Men with Metabolic and Anthropometric Disorders
  申请人：Meehan Alan

  公开号：US20080125403A1

  公开（公告）日：2008-05-29

  A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the ‘insulin resistance syndrome’, and ‘syndrome X’), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural formula I, II, III, or IV is disclosed. The method is also concerned with the use of the 5alpha reductase inhibiting compound together with antidiabetic agents, lipid lowering agents, antihypertensive agents, antiobesity agents, testosterone, testosterone precursors, testosterone prodrugs, testosterone analogs, and other androgen receptor agonists for treating visceral adiposity, metabolic syndrome, type II diabetes and insulin resistance in men.